HR1476-119

Introduced

To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program.

119th Congress Introduced Feb 21, 2025

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

This bill, To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Immigration, Social Welfare.

Who Benefits and How

health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.

Who Bears the Burden and How

federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.

Key Provisions

  • Section HCB9FBDBD90CC4703975CBBFAD28E1264: 1. Short title This Act may be cited as the Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act.
  • Section H41DFC03277DB49EFB40209E92592C147: 2. Phase-in for plasma-derived products under manufacturer discount program Section 1860D–14C(g)(4) of the Social Security Act (42 U.S.C. 1395w–114c(g)(4)) is...

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

This bill, To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program., changes federal law or congressional policy affecting health care providers and patients.

Key Policy Areas

Healthcare, Immigration, Social Welfare

Primary Purpose

This bill, To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program., changes federal law or congressional policy affecting health care providers and patients.

Policy Domains

Healthcare Immigration Social Welfare

Whole bill

Identified Gains
  • health care providers and patients
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
health care providers and patients:
Identified Costs
  • federal implementing agencies
  • health care providers and patients
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
federal implementing agencies:
health care providers and patients:

Legislative Progress

Introduced
Introduced Committee Passed
Feb 21, 2025

Mr. Hudson (for himself, Mr. Davis of North Carolina, Mr. …

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Transportation
1 mention across 1 clause
+1 positive

U.S.-flag vessel operators

China
1 mention across 1 clause
-1 negative

Vessels from China/Russia/Iran/DPRK

1/2
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Immigration Social Welfare
Actor Mappings
"federal_implementing_agencies"
→ Federal agencies assigned duties by the bill

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology